Simon T. Durrant

Butterfield St
Brisbane, QLD, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study.

Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study.

Journal: Internal medicine journal
Published: February 01, 2026

Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era.

Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era.

Journal: Internal medicine journal
Published: May 04, 2024

Quantifying skin cancer risk following allogeneic haematopoietic cell transplant in Queensland, Australia.

Quantifying skin cancer risk following allogeneic haematopoietic cell transplant in Queensland, Australia.

Journal: Bone marrow transplantation
Published: August 02, 2023

High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell transplantation.

High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell transplantation.

Journal: Bone marrow transplantation
Published: February 24, 2022

Activity and outcomes of autologous stem cell transplantation in the private sector in Australia.

Activity and outcomes of autologous stem cell transplantation in the private sector in Australia.

Journal: Internal medicine journal
Published: August 01, 2021

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis.

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis.

Journal: Blood
Published: September 08, 2020

Pegylated interferon-2α invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation.

Pegylated interferon-2α invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation.

Journal: Blood advances
Published: May 15, 2019

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis.

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis.

Journal: Haematologica
Published: May 11, 2019

Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.

Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.

Journal: Leukemia & lymphoma
Published: April 06, 2019

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

Journal: The Lancet. Haematology
Published: March 08, 2019

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.

Journal: British journal of haematology
Published: July 10, 2018

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.

Journal: Annals of hematology
Published: December 18, 2017
Showing 1-12 of 39

Last Updated: 09/26/2026